The expression, clinical relevance, and prognostic significance of HJURP in cholangiocarcinoma

Yang Yang, Jinyan Yuan, Zhenzhong Liu, Wenwen Cao, Pei LiuFrontiers in Oncology 2022 · DOI

TL;DR

Researchers have identified the Holliday junction recognition protein (HJURP) as a potent, subtype-specific prognostic biomarker for cholangiocarcinoma (bile duct cancer). While high HJURP expression strongly predicts poor survival in intrahepatic and perihilar subtypes, it appears to have little prognostic value in distal cases, highlighting the critical need for subtype-specific clinical management.

What Problem Does This Paper Address?

Cholangiocarcinoma (CCA) is a highly aggressive malignancy of the biliary tree with a notoriously poor prognosis. Historically, CCA has been treated as a somewhat monolithic disease, but it is actually a trio of distinct subtypes based on anatomical location: intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA).

The challenge lies in the fact that these subtypes exhibit different molecular landscapes and clinical behaviors. Current biomarkers often fail to account for this heterogeneity. The authors sought to investigate whether HJURP—a protein known to facilitate chromosome segregation during mitosis and implicated in other cancers—could serve as a reliable prognostic tool to help clinicians identify high-risk patients within these specific CCA subsets.

Methods

The study employed a dual-track approach combining bioinformatics and traditional pathology:

  1. In Silico Analysis: The team first validated HJURP mRNA expression levels using public datasets, including TCGA (The Cancer Genome Atlas) and Gene Expression Omnibus (GEO) series (GSE33327 and GSE132305).
  2. Clinical Cohort: They analyzed a retrospective cohort of 127 CCA patients (32 iCCA, 71 pCCA, and 24 dCCA) who underwent radical surgery between 2014 and 2019.
  3. Protein Detection: Using Tissue Microarrays (TMA) and Immunohistochemistry (IHC), the researchers quantified HJURP protein levels in tumor tissues.
  4. Statistical Modeling: They utilized Kaplan-Meier curves for survival analysis and Cox proportional hazards regression to determine if HJURP was an independent predictor of survival (meaning its predictive power holds up even when considering tumor size, stage, and grade).

Datasets

  • Internal Patient Cohort: 127 consecutive CCA patients from Qilu Hospital and the Second Affiliated Hospital of Shandong First Medical University.
  • TCGA/GEPIA: Used for broad pan-cancer and CCA vs. normal tissue mRNA comparisons.
  • GSE33327 & GSE132305: Specific mRNA-seq datasets used to validate expression in iCCA and extrahepatic CCA (ehCCA).

Key Insights and Ideas

  • The Subtype Divide: The most significant "aha moment" was the divergence in HJURP’s utility. It was a powerful independent prognostic factor for iCCA and pCCA, but not for dCCA. This reinforces the growing consensus that dCCA may be biologically distinct from its more proximal counterparts.
  • Cytoplasmic Mystery: HJURP is traditionally a nuclear protein that acts as a chaperone for CENP-A (essential for centromere function). However, IHC staining revealed that HJURP was primarily located in the cytoplasm of CCA cells. This suggests that in the context of malignancy, HJURP might take on non-canonical roles or that its translocation is a hallmark of tumor progression.
  • Independent Risk Factor: High HJURP expression wasn't just a byproduct of a larger tumor or a higher stage. Even after adjusting for those variables, patients with high HJURP were significantly more likely to suffer CCA-related death.

Key Results

  • Upregulation: HJURP is significantly overexpressed in CCA tissues compared to para-tumor (normal) tissues across both internal samples and public databases.
  • Survival Impact: In iCCA and pCCA, high HJURP expression correlated with much lower 3-year overall survival (OS) rates.
  • Hazard Ratios (HR):
    • In iCCA, high HJURP carried an HR of 5.23 (p=0.041), meaning these patients were over five times more likely to die during the follow-up period than those with low expression.
  • In pCCA, the HR was 3.25 (p=0.009).
  • Clinical Correlation: High HJURP levels were specifically associated with advanced "T stage" (tumor infiltration depth) in iCCA.

Limitations and Future Work

The authors acknowledge several hurdles that remain:

  • Sample Size: The dCCA subgroup was relatively small (n=24). It is possible that HJURP does have prognostic value in distal cases, but the study lacked the statistical power to detect it.
  • Mechanistic Gap: While the study proves a correlation between HJURP and poor outcomes, it does not explain how HJURP drives CCA progression. The authors suggest future research should look into signaling pathways like MAPK/ERK or AKT/GSK3β, which have been linked to HJURP in other cancers.
  • Single-Center Bias: Although the cohort was consecutive, a larger, multi-center prospective study is needed to validate these findings before HJURP can be used in routine clinical decision-making.

In summary, this paper moves the needle toward precision oncology in bile duct cancer by providing a new tool to risk-stratify patients based on their specific tumor subtype.

Summary updated

Abstract

HJURP was an independent prognostic biomarker in both iCCA and pCCA, but not in dCCA. Our results provide more evidence of the molecular features of different CCA subsets and suggest that patients with high HJURP are more high-risk, which can guide more precision follow-up and treatment of CCA.
BibTeX
@inproceedings{yang2022expression,
  author = {Yang Yang and Jinyan Yuan and Zhenzhong Liu and Wenwen Cao and Pei Liu},
  title = {{The expression, clinical relevance, and prognostic significance of HJURP in cholangiocarcinoma}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.972550},
}
Figure